Osseon Therapeutics Inc. has formed an international distribution agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE Mark-approved device, the Osseoflex SB steerable balloon.
Aesculap, a division of B. Braun Melsungen, a large medical and pharmaceutical company headquartered in Tuttlingen, Germany, will distribute the devices in parts of Europe and Asia.
"Aesculap is a major medical device company known throughout the world as a quality manufacturer and distributor of surgical instruments. Our new Osseoflex SB represents the most precise and controllable treatment device for vertebral compression fracture augmentation currently available to surgeons,” said John Stalcup, Ph.D., Osseon's CEO. “Osseon is very excited to partner with Aesculap to distribute our game-changing Osseoplasty devices and procedures for VCF treatment to patients throughout Europe and the international community and provide state-of-the-art alternatives to the cumbersome devices and procedures currently used to treat fractures of the thoracic and lumbar spine."
B. Braun is one of the world´s largest healthcare suppliers. The company’s products focus on four areas: hospital, surgery, private practice (medical care and doctors´ offices) and extracorporeal blood treatment. Aesculap's product range includes surgical instruments for open or minimally invasive approaches, implants (e.g., for orthopedics, neurosurgery and spinal surgery), surgical sutures, sterile container, storage, motor and navigation systems as well as products for cardiology.
Osseon Therapeutics focuses on minimally invasive treatments for degenerative bone and joint disease. The company is headquartered in Santa Rosa, Calif. Its products have received U.S. Food and Drug Administration clearance and the CE Mark for product distribution in the United States and the European Union.